
๐ซ๐ท ๐บ๐ธ GI oncologist MD PhD #PancreaticCancer #Bioinformatics #ImageAnalysis #DigitalPathology #SingleCell #TCRSeq #SpatialTranscriptomics #Microbiota
MSKCC, Manhattan, NY, USA
Joined September 2021
- Tweets373
- Following178
- Followers204
- Likes818
Pinned Tweet
After almost 1 year @MSKCancerCenter @CpcrMsk ๐
Honored to present at #AACRpan25 uncovering mechanisms of resistance & response on the POLAR trial.
Exciting 2nd year ahead!
@CentralParkWMD @EileenMOReilly @ciacobu @jmsongmd @CatherineaOC
@MichaelMayMD
#PancreaticCancer
Marc Hilmi retweeted
๐ฅ PRIME-HCC - The Lancet Oncology
๐ Nivolumab ร2 cycles + ipilimumab once, before resection of early-stage HCC
๐ฅ 33 patients, Phase 1b, safety primary endpoint
โ
30 of 33 (91%) reached surgery; grade 3 trAEs 9%, no grade 4โ5
๐ ORR 25%, disease control 97%
๐ฉธ ctDNA-negative after surgery: 2-year RFS 82% vs 29%
โ ๏ธ Single arm, 18 patients in the ctDNA comparison
Most of our patients with resectable HCC go straight to surgery and then wait to see whether it comes back, which happens far too often.
- PRIME-HCC shows dual checkpoint blockade before resection is safe enough: 91% reached the operating room and grade 3 toxicity was 9%. This is the main finding of a phase 1 trial.
- A 25% response rate in 33 pts is not efficacy, and the authors say so.
- The part I find most useful is ctDNA: clearance after surgery split 2-year RFS 82% vs 29%, though on 18 evaluable patients.
That is a hypothesis for selecting who needs adjuvant therapy, not yet a test to act on.
#HCC #LiverCancer #Immunotherapy #ctDNA #GIOnc
thelancet.com/journals/lanonโฆ
Marc Hilmi retweeted
AmCORE Study: Age-Related Outcomes in Colorectal Liver Metastases
A retrospective AmCORE-based study evaluated treatment patterns and survival outcomes in 351 patients with colorectal liver metastases (CRLM) across three age groups: <50, 50โ69, and โฅ70 years.
Key findings:
โซ๏ธ Induction systemic therapy: 58.1% of patients aged <50 years received treatment, compared with 40.5% and 21.8% in the older age groups (P < 0.001).
โซ๏ธ Disease burden: Younger patients had more liver metastases at diagnosis (median 4 vs 2 vs 2; P = 0.030).
โซ๏ธ PFS: Differed significantly across age groups, with shorter PFS in patients aged <50 years (P = 0.019).
โซ๏ธ OS: No significant difference across age groups (P = 0.22), despite differences in treatment intensity.
Takeaway: Younger patients received more intensive systemic therapy but experienced shorter PFS, while OS remained comparable across age groups. Greater disease burden at diagnosis may partly explain these findings, supporting individualized treatment decisions based on disease characteristics rather than age alone.
@rj_swijnenburg @TBuffart
oncodaily.com/gastrointestinโฆ
#AmCORE #ColorectalCancer #GIOncology
Marc Hilmi retweeted
๐ Onvansertib - FDA Fast Track
๐ฏ First-line KRAS- or NRAS-mutated metastatic CRC
๐ Onvansertib (PLK1 inhibitor) + FOLFIRI/bevacizumab
๐ Randomised Phase 2 CRDF-004 trial
โ
Confirmed ORR 72.2% vs 42.1% with FOLFIRI/bev alone
โฑ๏ธ Median PFS not reached vs about 11 months, company-reported and immature
โ ๏ธ A designation, not an approval
Most patients with RAS-mut mCRC, whether left- or right-sided, who have no actionable target receive first-line chemo + bevacizumab. A 30%-point ORR gain in a randomized phase 2 trial is a real signal, and Fast Track designation should facilitate discussions with the FDA.
But a designation is not an approval, ORR is not survival, and the PFS comparison is company-reported and still immature.
The question I want answered in phase 3 is whether those extra responses translate into more time for patients or enable more of them to undergo liver resection..
Btw:
Open at Moffitt (for 1L mCRC KRAS-mut):
โข ROSETTA CRC-203: Pumitamig + Chemo vs Bevacizumab + Chemo in 1L Metastatic CRC (MMRp/MSS, BRAF WT) - NCT07221357
โข ERAS-0015 (Pan-RAS Molecular Glue) ยฑ Pembrolizumab or Panitumumab in RAS-Mutant Advanced Solid Tumors (AURORAS-1) - NCT06983743
โข VS-7375 (Oral KRAS G12D ON/OFF Inhibitor) ยฑ Anti-EGFR Antibody in KRAS G12D-Mutated Metastatic CRC (TARGET-D 203) - NCT07659795
- - - [email protected]
- - trials.allanpereira.com
#CRC #mCRC #KRAS #GIOnc
globenewswire.com/news-releaโฆ
Marc Hilmi retweeted
Drinking is bad for immunotherapy @BenjaminGVincen
science.org/doi/10.1126/scisโฆ
Marc Hilmi retweeted
Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers
revmed.com/media/news/13736/โฆ
Marc Hilmi retweeted
The European Commission has approved daraxonrasib (RASONQUEยฎ), the first broad RAS-targeted therapy for metastatic pancreatic cancer
An important milestone for patients with pancreatic adenocarcinoma ๐
A promising step forward!
#PancreaticCancer
@RevMedicines
Marc Hilmi retweeted
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR CRC: pls 2 UNICORN trial
@NatureMedicine
๐pMR rate:
0% in pMMR BOT
36% in pMMR BOT + BAL
36% in dMMR BOT
100% in dMMR BOT + BAL
๐งinteresting efficacy for BOT + BAL in early pMMR or dMMR CC
@myESMO @ASCO
Marc Hilmi retweeted
Look at these curves - ๐ฅ NICHE-2 at five years - Phase 2 (The Lancet)
๐ฏ Stage IIโIII dMMR colon cancer, before surgery
๐ Ipilimumab ร1 + nivolumab ร2, then resection
๐ฅ 111 per-protocol patients, six Dutch hospitals
โ
3-year DFS 100% at a median 58.7 mo
โ
5-year OS 100% (exploratory)
๐ฉธ ctDNA cleared in 80/97 before surgery, all negative after
โ ๏ธ Single-arm, no comparator
The pathological response rates from NICHE-2 were already striking; this is the survival follow-up that tells us they held.
Zero recurrences across 111 patients, after only roughly a month of treatment w/o chemo before surgery.
The comparison that now matters is with *ATOMIC*, which added atezolizumab to adjuvant FOLFOX after surgery: two routes to curing dMMR colon cancer, one of them with six months of chemotherapy and one without.
NICHE-2 is single-arm, so one can say that a randomized comparison is still owed before it replaces surgery-first.
#CRC #dMMR
thelancet.com/journals/lanceโฆ
Marc Hilmi retweeted
5/6
Cancer vaccines could eventually move into prevention or interception:
"In theory, a vaccine against 25 recurrent mutational hotspots in genes such as KRAS, BRAF, and PIK3CA could target mutations found in more than 70% of colorectal, pancreatic, uterine, and melanoma..."
Marc Hilmi retweeted
๐ง โก Where great minds meet and ideas sPARK!
Incredible few days at @CSHL at Banbury with @lustgartenfdn!
A small room filled with epic minds who shaped the last 20 years and brilliant new minds shaping the next 5โ10 years of #PancreaticCancer research. Bert Vogelstein @ldiaz1971 Liz Jaffee Nilo Azad @DavidHongMD Jenifer Knox Erica Tsang Harshabad Singh Brian Wolpin Andy Aguirre David Tuveson Dan Nussenbaum @DrDanielKing Vincent Bernard and more~~
From #KRAS biology and resistance to new therapeutic strategies, to interception, the science was deep and the discussions even deeper!
Came to learn from the legends and left thinking differently myself. ๐๐
The best science doesnโt just answer questions. It changes how we think.
#PDAC #RAS #TeamScience @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk
Marc Hilmi retweeted
Thanks @DoctorKvoss and @preprintclub for highlighting our work and for the great feedback!
Check out our preprint highlight piece on iron metabolism in T cells in pancreas cancer ๐ฅ nature.com/articles/s41577-0โฆ
Marc Hilmi retweeted
From POLAR to AURORA, Dr. Wungki Park (@CentralParkWMD) from @MSKCancerCenter explores the connections between DNA repair and tumor immunity. #BRCASymposium
Marc Hilmi retweeted
โญ Eileen OโReilly, MD, of @MSKCancerCenter reviews findings from the AMPLIFY-7P trial evaluating #camupepimut in resected KRAS-mutated #PDAC.
๐บ Watch Dr. OโReilly discuss the link between immune activation and clinical benefit: buff.ly/NQvyGkd
Marc Hilmi retweeted
Via @NatPancFdn, a webinar tomorrow, 11 Nov 2026, 6PM Eastern. Advances in genetic testing, precision medicine, targeted therapies, immunotherapy, vaccines, & other approaches. Register here:
zoom.us/webinar/register/WN_โฆ
Marc Hilmi retweeted
Antibiotics and outcomes of cancer immunotherapy:
An updated meta-analysis and clinical applications
@Cancer_Cell
doi.org/10.1016/j.ccell.2026โฆ
๐Interesting perspective
๐Detrimental effect on PFS & OS
๐Time to consider gut microbiome
๐งWe need strategies to mitigate antibiotic-induced dysbiosis and preserve ICI responses
@myESMO @ASCO
Marc Hilmi retweeted
๐ฅ @nyulangone Perlmutter Cancer Center has appointed @VivekSubbiah, MD, Director of Early-Phase Drug Development and Rare Cancer Programs.
๐ฉบ He brings 15+ years of experience in #PrecisionOncology and clinical research.
Learn more โก๏ธ ascopost.com/news/november-2โฆ
Marc Hilmi retweeted
More targets for #PDAC!
And evidence that #ECM components like fibrin are signals as well as scaffolds
nature.com/articles/s41586-0โฆ
Marc Hilmi retweeted
Congratulations @FASinicropeMD @ALLIANCE_org - Alliance GI committee- highlighting the importance of federally funded practice changing NCI studies - ATOMIC - new adjuvant standard in MSI-H/dMMR colon @NEJM @NCCN @FDA nice to see highlighted in plenary session!
Marc Hilmi retweeted
Second player in this space - excited for most recent update for zoci (DLL3 ADC) phase 1b/2 program: 40% RR, mDOR 5.6 mo in chemorefractory pts, activity seen in DLL3-low/negative pts as well. Frontline cohort now open, phase 3 designs being discussed. #NANETS2026
Marc Hilmi retweeted
โจ Excited to share new work in @NatureGenet, with next-door neighbor @SohrabShah! Our labs โ led by @nceglia; @GreedyApple; Zach Sethna; and @elhanati_yuval - applied information theory and probabilistic modeling to the question of how T cell dynamics changes in response to immunotherapy, particularly coupling between a T cell's T cell receptor (TCR) and its phenotypic state.
T cell responses are critical to cancer immunotherapies. Their behavior is often strongly influenced by their TCR, which directly engages with antigens presented on the cell surface. How clonal the sequenced TCR repertoire is in a dataset has been used to understand response โ TCRs that recognize an antigen multiply โ but its often a noisy measure, and we wanted to extend this logic to single-cell data in an eqiposed way. Information theory offers a solution.
The specific question of how information is propagated between the TCR and its phenotypic state also becomes a general way to probe genotype-phenotype mapping. The mutual information between receptor and state - that is how much knowing about one tells you information about the other - and how that changes can then be used to probe therapeutic response. Given data sparsity this becomes a problem in probabilistic inference โ which was addressed here via a cool hierarchical Bayesian framework led by @GreedyApple & @nceglia.
A flux in phenotype and stronger mutual information post-treatment was associated with response to immunotherapy. In non-responders, therapy did not improve poor communication between TCR and phenotype. Hence information dynamics can be used to measure response.
We are already collectively using this approach across many, many projects. We use variants to analyze vaccine data with @TheVinodLab at the Olayan Center for Cancer Vaccines @MSKCancerCenter, in multiple projects with @break_cancer, throughout the Halvorsen Center @CompOncMSK, and elsewhere. It was a lot of fun and we hope you enjoy! Code link included! ๐ ๐ ๐
nature.com/articles/s41588-0โฆ





































